Fenton SE - Search Results

1

Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?

Fenton SE, Hussain M. Fenton SE, et al. Expert Opin Investig Drugs. 2024 Oct;33(10):993-999. doi: 10.1080/13543784.2024.2391828. Epub 2024 Aug 20. Expert Opin Investig Drugs. 2024. PMID: 39135527 Review.

2

PARP Inhibition in Advanced Prostate Cancer.

Fenton SE, Chalmers ZR, Hussain M. Fenton SE, et al. Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560. Cancer J. 2021. PMID: 34904808 Review.

3

Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?

Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C. Hussain M, et al. Among authors: fenton se. J Clin Oncol. 2022 Sep 10;40(26):3011-3014. doi: 10.1200/JCO.22.00208. Epub 2022 Apr 19. J Clin Oncol. 2022. PMID: 35439030 No abstract available.

4

Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm.

Serritella AV, Fenton SE, Hussain M. Serritella AV, et al. Among authors: fenton se. Eur Urol Focus. 2023 May;9(3):407-408. doi: 10.1016/j.euf.2023.01.009. Epub 2023 Jan 25. Eur Urol Focus. 2023. PMID: 36707276

5

Emerging growth factor receptor antagonists for the treatment of advanced melanoma.

Fenton SE, Sosman JA, Chandra S. Fenton SE, et al. Expert Opin Emerg Drugs. 2017 Jun;22(2):165-174. doi: 10.1080/14728214.2017.1336537. Expert Opin Emerg Drugs. 2017. PMID: 28562096 Review.

6

First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.

Weiner AB, Siebert AL, Fenton SE, Abida W, Agarwal N, Davis ID, Dorff TB, Gleave M, James ND, Poon DMC, Suzuki H, Sweeney CJ. Weiner AB, et al. Among authors: fenton se. Eur Urol Oncol. 2022 Aug;5(4):377-387. doi: 10.1016/j.euo.2022.04.009. Epub 2022 May 28. Eur Urol Oncol. 2022. PMID: 35641398 Review.

7

Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access.

Fenton SE, VanderWeeler DJ, Rebbeck TR, Chen DL. Fenton SE, et al. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433138. doi: 10.1200/EDBK_433138. Am Soc Clin Oncol Educ Book. 2024. PMID: 38781539 Free article. Review.

8

Epidemiology, mutational landscape and staging of hepatocellular carcinoma.

Fenton SE, Burns MC, Kalyan A. Fenton SE, et al. Chin Clin Oncol. 2021 Feb;10(1):2. doi: 10.21037/cco-20-162. Chin Clin Oncol. 2021. PMID: 33541087 Free article. Review.

9

Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.

Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, Horvath CM, Le Poole IC, Bosenberg M, Bartom ET, Kocherginsky M, Platanias LC, Saleiro D. Fenton SE, et al. Mol Cancer Res. 2023 Apr 1;21(4):332-344. doi: 10.1158/1541-7786.MCR-22-0684. Mol Cancer Res. 2023. PMID: 36573964 Free PMC article.

10

Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma.

Fenton SE, VanderWeele DJ. Fenton SE, et al. Front Oncol. 2023 Jan 4;12:1069356. doi: 10.3389/fonc.2022.1069356. eCollection 2022. Front Oncol. 2023. PMID: 36686762 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters